Correlation
The correlation between DXCM and LLY is 0.49, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
DXCM vs. LLY
Compare and contrast key facts about DexCom, Inc. (DXCM) and Eli Lilly and Company (LLY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: DXCM or LLY.
Performance
DXCM vs. LLY - Performance Comparison
Loading data...
Key characteristics
DXCM:
-0.48
LLY:
-0.23
DXCM:
-0.39
LLY:
-0.04
DXCM:
0.93
LLY:
0.99
DXCM:
-0.52
LLY:
-0.32
DXCM:
-0.86
LLY:
-0.59
DXCM:
37.95%
LLY:
13.61%
DXCM:
58.62%
LLY:
38.49%
DXCM:
-94.61%
LLY:
-68.27%
DXCM:
-47.30%
LLY:
-22.74%
Fundamentals
DXCM:
$34.11B
LLY:
$648.68B
DXCM:
$1.30
LLY:
$12.28
DXCM:
65.28
LLY:
58.84
DXCM:
1.34
LLY:
1.10
DXCM:
8.22
LLY:
13.24
DXCM:
15.05
LLY:
40.97
DXCM:
$4.15B
LLY:
$49.00B
DXCM:
$2.46B
LLY:
$40.03B
DXCM:
$889.80M
LLY:
$16.27B
Returns By Period
In the year-to-date period, DXCM achieves a 10.33% return, which is significantly higher than LLY's -4.09% return. Over the past 10 years, DXCM has underperformed LLY with an annualized return of 16.81%, while LLY has yielded a comparatively higher 27.48% annualized return.
DXCM
10.33%
20.20%
10.01%
-27.53%
4.83%
-1.93%
16.81%
LLY
-4.09%
-17.77%
-6.90%
-8.88%
34.17%
38.59%
27.48%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
DXCM vs. LLY — Risk-Adjusted Performance Rank
DXCM
LLY
DXCM vs. LLY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for DexCom, Inc. (DXCM) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
DXCM vs. LLY - Dividend Comparison
DXCM has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.76%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
DXCM DexCom, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LLY Eli Lilly and Company | 0.76% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.95% | 2.46% | 2.77% | 2.37% | 2.84% |
Drawdowns
DXCM vs. LLY - Drawdown Comparison
The maximum DXCM drawdown since its inception was -94.61%, which is greater than LLY's maximum drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for DXCM and LLY.
Loading data...
Volatility
DXCM vs. LLY - Volatility Comparison
DexCom, Inc. (DXCM) and Eli Lilly and Company (LLY) have volatilities of 16.55% and 16.63%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
DXCM vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between DexCom, Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
DXCM vs. LLY - Profitability Comparison
DXCM - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, DexCom, Inc. reported a gross profit of 589.00M and revenue of 1.04B. Therefore, the gross margin over that period was 56.9%.
LLY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported a gross profit of 10.50B and revenue of 12.73B. Therefore, the gross margin over that period was 82.5%.
DXCM - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, DexCom, Inc. reported an operating income of 133.70M and revenue of 1.04B, resulting in an operating margin of 12.9%.
LLY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported an operating income of 5.41B and revenue of 12.73B, resulting in an operating margin of 42.5%.
DXCM - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, DexCom, Inc. reported a net income of 105.40M and revenue of 1.04B, resulting in a net margin of 10.2%.
LLY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported a net income of 2.76B and revenue of 12.73B, resulting in a net margin of 21.7%.